Prophylactic Tocilizumab in MajesTEC-1 for the Reduction of CRS

Opinion
Video

Panelists discuss how prophylactic use of tocilizumab in the MajesTEC-1 trial may reduce the incidence and severity of cytokine release syndrome (CRS) in patients receiving bispecific antibody therapy for multiple myeloma, potentially improving treatment safety and tolerability.

Recent Videos
Related Content